Padesvonil

Unassigned

New Medicines

Focal-onset seizures in patients with drug-resistant epilepsy

Information

New molecular entity
UCB Pharma
UCB Pharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

First-in-class inhibitor of seizure activity by presynaptic modulation of all three SV2 isoforms and postsynaptic enhancement of GABA‐mediated inhibition [2].
The prevalence of active epilepsy is 5-10 cases per 1,000 - but with 5-30% of these misdiagnosed as having epilepsy [1].
Focal-onset seizures in patients with drug-resistant epilepsy
Oral